United Services Automobile Association raised its holdings in BioTelemetry Inc (NASDAQ:BEAT) by 8.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,984 shares of the medical research company’s stock after acquiring an additional 595 shares during the quarter. United Services Automobile Association’s holdings in BioTelemetry were worth $477,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also modified their holdings of BEAT. Financial Architects Inc acquired a new stake in BioTelemetry in the 4th quarter valued at about $30,000. Altshuler Shaham Ltd lifted its holdings in BioTelemetry by 1,883.8% in the 4th quarter. Altshuler Shaham Ltd now owns 2,321 shares of the medical research company’s stock valued at $42,000 after acquiring an additional 2,204 shares during the last quarter. We Are One Seven LLC acquired a new stake in BioTelemetry in the 4th quarter valued at about $44,000. Parkside Financial Bank & Trust lifted its holdings in BioTelemetry by 4,904.3% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,151 shares of the medical research company’s stock valued at $69,000 after acquiring an additional 1,128 shares during the last quarter. Finally, Meeder Asset Management Inc. acquired a new stake in BioTelemetry in the 4th quarter valued at about $108,000. 88.51% of the stock is owned by institutional investors.
BEAT has been the subject of a number of research analyst reports. BidaskClub downgraded shares of BioTelemetry from a “strong-buy” rating to a “buy” rating in a report on Tuesday, December 18th. Zacks Investment Research downgraded shares of BioTelemetry from a “buy” rating to a “hold” rating in a report on Monday, February 4th. ValuEngine raised shares of BioTelemetry from a “buy” rating to a “strong-buy” rating in a report on Monday, February 4th. Sidoti set a $95.00 price target on shares of BioTelemetry and gave the company a “buy” rating in a report on Tuesday, February 5th. Finally, Lake Street Capital set a $90.00 price target on shares of BioTelemetry and gave the company a “buy” rating in a report on Friday, February 22nd. One research analyst has rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the stock. BioTelemetry presently has an average rating of “Buy” and a consensus target price of $75.67.
BEAT stock opened at $58.58 on Tuesday. The company has a quick ratio of 2.81, a current ratio of 2.96 and a debt-to-equity ratio of 0.62. BioTelemetry Inc has a one year low of $30.30 and a one year high of $80.92. The stock has a market cap of $2.11 billion, a price-to-earnings ratio of 30.20 and a beta of 1.44.
BioTelemetry (NASDAQ:BEAT) last posted its quarterly earnings data on Thursday, February 21st. The medical research company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.43 by $0.13. BioTelemetry had a net margin of 10.72% and a return on equity of 24.46%. The company had revenue of $103.60 million during the quarter, compared to analyst estimates of $102.84 million. During the same period in the prior year, the firm earned $0.32 earnings per share. The business’s quarterly revenue was up 13.0% on a year-over-year basis. Sell-side analysts predict that BioTelemetry Inc will post 1.94 EPS for the current year.
TRADEMARK VIOLATION NOTICE: “BioTelemetry Inc (BEAT) Shares Bought by United Services Automobile Association” was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://sportsperspectives.com/2019/04/02/biotelemetry-inc-beat-shares-bought-by-united-services-automobile-association.html.
BioTelemetry, Inc, a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology.
Featured Story: What are convertible shares?
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.